Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised …
AL Wilkinson, K Zaman, M Hoque… - The Lancet Infectious …, 2023 - thelancet.com
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised …
AL Wilkinson, K Zaman, M Hoque, CF Estivariz… - 2023 - pubmed.ncbi.nlm.nih.gov
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Immunogenicity of novel oral Poliovirus vaccine type 2 administered concomitantly with bivalent oral Poliovirus vaccine: an open-label, non-inferiority, randomised …
AL Wilkinson, K Zaman, M Hoque, CF Estivariz… - 2023 - cabidigitallibrary.org
Background: Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised …
AL Wilkinson, K Zaman, M Hoque, CF Estivariz… - The Lancet Infectious …, 2023 - Elsevier
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised …
AL Wilkinson, K Zaman, M Hoque… - The Lancet. Infectious …, 2023 - europepmc.org
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …